Remdesivir is a antiviral medication that is nucleotide analog broad spectrum and in 2020 , it is being tested as treatment for COVID 19, as well as has been authorized for emergency use in the America but legally it’s not yet approved in U.S. Beside this it has been approved for use in Japan for people with severe symptoms that develop during pandemic COVID 19.
It’s thought that using of this drug shorten the duration of recovery time than the usual.This medicine i.e antiviral compound that are undergoing clinical trials in lots of countries as a potential treatment for COVID-19 cases.
It’s uses in having antiviral activity that is against various RNA viruses consisting SARS corona virus as well as MERS coronavirus, still research is not yet proved it’s well benefits.It’s developed usually in order for treatment of hepatitis C.
Beside these Remdesivir was used in Ebola & Marburg virus disease , but was not so effective for all of those viral infections.Gilead Sciences discovered that remdesivir had antiviral activity in vitro against various types filovirus, pneumoviruses, paramyxoviruses, and as well as coronaviruses as well.
March 2020, a little trial of remdesivir in rhesus macaque monkeys with COVID‑19 infections and there got that it prevents disease progression. In 18 March 2020, the (WHO) announced the launch of a trial that would consist one group which was treated with remdesiv as was quit helpful.
Remdesivir was effective against various kinds of corona viruses in cell culture & in a mouse model of SARS & did not shows toxic.
How does it work in corona virus treatment
According to the various researchers, it inhibits the replication process in their model of the corona virus that causes MERS.
Following clinical studies going on COVID19 management by using Remdesivir.
Severe 2019-nCoV Remdesivir RCT China-Japan Friendship Hospital – Beijing, China
Mild/Moderate 2019-nCoV Remdesivir RCT Jin Yin-tan Hospital – Wuhan, China
Adaptive COVID-19 Treatment Trial University of Nebraska Medical Center – Omaha NE, USA
Expanded Access Remdesivir (RDV; GS-5734™) U.S. Army Medical Research and Development Command
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Corona virus Disease (COVID-19) Gilead Sciences, Inc.
Adaptive COVID-19 Treatment Trial National Institute of Allergy and Infectious Diseases (NIAID).
Usually common adverse effects while studying of remdesivir for COVID‑19 case that conclude respiratory failure & organs impairment, having reduced albumin , less potassium, reduces RBcs counts and reduces platelets count as well and that help with clotting effect beside these it also causes skin discoloration.
Others adverse effects such as GIT distress problems, increases transminase level and that’s tells sign of inflammation or damage to cells in the liver. Beside these inusion‐related reactions. Infusion‐related reaction Signs & symptoms of this reaction consists low BP( hypotension), nausea, vomiting sweating, as well as shivering.